These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 2845611

  • 1. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
    Chulay JD, Fleckenstein L, Smith DH.
    Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
    [Abstract] [Full Text] [Related]

  • 2. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K, Vieira FA, Porrozzi R, Marchevsky RS, Miekeley N, Grimaldi G, Paumgartten FJ.
    J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
    [Abstract] [Full Text] [Related]

  • 3. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat.
    Miranda ES, Miekeley N, De-Carvalho RR, Paumgartten FJ.
    Reprod Toxicol; 2006 Apr; 21(3):292-300. PubMed ID: 16271447
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate.
    Zaghloul IY, Radwan MA, Al Jaser MH, Al Issa R.
    J Clin Pharmacol; 2010 Nov; 50(11):1230-7. PubMed ID: 20663995
    [Abstract] [Full Text] [Related]

  • 5. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
    Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlé F.
    Vet Parasitol; 2006 Jan 30; 135(2):137-46. PubMed ID: 16242844
    [Abstract] [Full Text] [Related]

  • 6. Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters.
    Alnaim L, Abou Alsoud N, Zaghloul I, Al-Jaser M.
    Int J Antimicrob Agents; 2007 Jun 30; 29(6):728-32. PubMed ID: 17369029
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of experimental visceral leishmaniasis in the opossum.
    White MR, Chapman WL, Hanson WL.
    J Parasitol; 1989 Feb 30; 75(1):176-8. PubMed ID: 2918440
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of visceral leishmaniasis in children].
    Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM.
    Med Trop (Mars); 2007 Feb 30; 67(1):73-8. PubMed ID: 17506279
    [Abstract] [Full Text] [Related]

  • 9. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies.
    Frézard F, Martins PS, Bahia AP, Le Moyec L, de Melo AL, Pimenta AM, Salerno M, da Silva JB, Demicheli C.
    Int J Pharm; 2008 Jan 22; 347(1-2):102-8. PubMed ID: 17656054
    [Abstract] [Full Text] [Related]

  • 10. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
    Valladares JE, Alberola J, Esteban M, Arboix M.
    Vet Rec; 1996 Feb 24; 138(8):181-3. PubMed ID: 8677619
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
    Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG.
    J Infect Dis; 2007 Feb 15; 195(4):602-8. PubMed ID: 17230422
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
    Valladares JE, Riera C, Alberola J, Gállego M, Portús M, Cristòfol C, Franquelo C, Arboix M.
    Vet Parasitol; 1998 Feb 15; 75(1):33-40. PubMed ID: 9566092
    [Abstract] [Full Text] [Related]

  • 13. Treatment of kala-azar in India.
    Thakur CP.
    Natl Med J India; 1992 Feb 15; 5(5):203-5. PubMed ID: 1338871
    [No Abstract] [Full Text] [Related]

  • 14. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
    Berhe N, Ali A, Hailu A, Yeneneh H.
    Acta Trop; 1994 Jun 15; 57(1):83-90. PubMed ID: 7942358
    [Abstract] [Full Text] [Related]

  • 15. [Visceral leishmaniasis: new drugs].
    Minodier P, Robert S, Retornaz K, Garnier JM.
    Arch Pediatr; 2003 Dec 15; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [Abstract] [Full Text] [Related]

  • 16. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
    Hantson P, Léonard ED, Crutzen-Fayt MC, Léonard A, Vandercam B, Delaere B, Mahieu P.
    Pharmacotherapy; 1996 Dec 15; 16(5):869-71. PubMed ID: 8888081
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
    Belloli C, Crescenzo G, Carli S, Zaghini A, Mengozzi G, Bertini S, Ormas P.
    Vet J; 1999 May 15; 157(3):315-21. PubMed ID: 10328843
    [Abstract] [Full Text] [Related]

  • 19. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL, Hanson WL, Alving CR, Hendricks LD.
    Am J Vet Res; 1984 May 15; 45(5):1028-30. PubMed ID: 6732008
    [Abstract] [Full Text] [Related]

  • 20. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC, Romero GA, Merchan-Hamann E, Magalhães AV, Macedo Vde O.
    Rev Soc Bras Med Trop; 1999 May 15; 32(4):383-7. PubMed ID: 10495667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.